Harbin Medisan Pharmaceutical Co., Ltd.

Total Valuation

Harbin Medisan Pharmaceutical Co., Ltd. carries a market capitalization of 3.10B, placing it among publicly traded companies globally. Its enterprise value stands at 4.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Harbin Medisan Pharmaceutical Co., Ltd. currently has 316.36M shares outstanding.

Valuation Ratios

Harbin Medisan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 100.33. The price-to-sales ratio is 4.47, and the price-to-book ratio stands at 5.94.

Enterprise Valuation

On an enterprise value basis, Harbin Medisan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 159.52 and an EV/FCF ratio of 15.59. The EV/Sales ratio of 4.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 159.52 provides insight into valuation relative to core operating earnings.

Financial Position

Harbin Medisan Pharmaceutical Co., Ltd. maintains a current ratio of 1.02, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.74, indicating elevated leverage, while an interest coverage ratio of -1.53 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Harbin Medisan Pharmaceutical Co., Ltd. has paid -2.71M in income taxes, reflecting an effective tax rate of 39.72.

Stock Price Statistics

Harbin Medisan Pharmaceutical Co., Ltd.'s stock has declined approximately -34.2953% over the past 52 weeks. The 50-day moving average sits at 10.54, while the 200-day moving average is 12.25.

Income Statement

Over the trailing twelve months, Harbin Medisan Pharmaceutical Co., Ltd. generated 1.02B in revenue and converted that into -59.99M in net income, yielding earnings per share of -0.20. EBITDA reached -45.06M, while operating income came in at -45.06M.

Balance Sheet

Harbin Medisan Pharmaceutical Co., Ltd. holds 586.69M in cash and equivalents against 838.26M in total debt, resulting in a net debt position of 265.29M. Total book value stands at 769.03M, with working capital of 18.98M providing operational flexibility.

Cash Flow

After subtracting -281.00M in capital expenditures, free cash flow totaled -281.00M - equivalent to -0.88 per share.

Margins

Harbin Medisan Pharmaceutical Co., Ltd. operates with a gross margin of 46.23, reflecting its pricing power and cost economics. The operating margin of -4.41 and net profit margin of -5.87 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -163.48 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Harbin Medisan Pharmaceutical Co., Ltd.'s most recent stock split took place on June 13, 2018 with a 2:3 split ratio.

Scores

Harbin Medisan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.21, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.